FIG (Factor Induced Gene) Therapeutics is a preclinical stage biotech developing a multimodal polynucleotide therapeutic that is driven by transcription factors overexpressed in cancer.

The main cancers affecting men and women are prostate and breast cancer, respectively. Unfortunately, even after removal of the tumor through surgery, high grade prostate and breast cancer have an extremely high rate of recurrence within 5 years (20-50%). Given that both of these cancers are caused by overexpression of certain transcription factors, the main medical therapy employed by pharmaceutical companies is to inhibit their function. Although these drugs work temporarily, and bring in over $20billion in yearly revenue, they almost unanimously cause development of resistance and more aggressive disease within 1-2 years.

At FIG Therapeutics, we do things differently. Rather than inhibit the main culprits behind the top cancers, we harness their function: to transcribe genes.

Our proprietary polynucleotide-based therapeutic has been designed to specifically recruit overexpressed cancer-causing transcription factors and drive transcription of a cocktail of multiple therapeutic genes that both induce potent antitumor immune cell recruitment and inhibit the immunosuppressive tumor microenvironment (the biggest hurdle in solid tumor immunotherapy).

In addition, given that the multimodal immunotherapy is driven by the overexpressed cancer-causing transcription factors, our approach not only prevents resistance, but also allows for cancer specificity with nonspecific delivery.